Brief: Appili Therapeutics Gets Notice Of Allowance From The U.S. Patent And Trademark Office For Co's Liquid Oral Reformulation
13/01/2023 12:37
Jan 13 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES NOTICE OF ALLOWANCE FROM THE
U.S.
PATENT AND TRADEMARK OFFICE FOR ATI-1501 LIQUID ORAL
REFORMULATION OF METRONIDAZOLE
* APPILI THERAPEUTICS INC - CO & SAPTALIS, EXPECT ATI-1501
TO BE
APPROVED BY FDA BY END OF 2023
Source text for Eikon: ID:nBw6788hNa
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez